ArticleOncology letters2017

Conversion to monotherapy with luteinizing-hormone releasing hormone agonist or orchiectomy after reaching PSA nadir following maximal androgen blockade is able to prolong progression-free survival in patients with metastatic prostate cancer: A propensity score matching analysis.

Gyeong Eun Min et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.